Biogen Inc. Drug Patent Portfolio
Biogen Inc. owns 1 purple book drug protected by 32 US patents Given below is the list of Biogen Inc.'s drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10844416 | Manganese supplementation for control of glycosylation in mammalian cell culture process | 01 Jun, 2036 | Active |
US11268119 | Copper supplementation for control of glycosylation in mammalian cell culture process | 21 Feb, 2036 | Active |
US11124760 | Methods for overcoming glutamine deprivation during mammalian cell culture | 27 Aug, 2035 | Active |
US10023831 | Gas delivery devices and associated systems and methods | 17 Mar, 2035 | Active |
US10676772 | Control of protein glycosylation by culture medium supplementation and cell culture process parameters | 19 Aug, 2034 | Active |
US9994968 | Electrochemical etching apparatus | 19 Aug, 2034 | Active |
US10119976 | Method of assessing risk of PML | 27 May, 2034 | Active |
US10677803 | Method of assessing risk of PML | 27 May, 2034 | Active |
US11280794 | Method of assessing risk of PML | 27 May, 2034 | Active |
US9562252 | Methods of preventing and removing trisulfide bonds | 11 May, 2033 | Active |
US10590454 | Methods of preventing and removing trisulfide bonds | 11 May, 2032 | Active |
US9790533 | Methods of preventing and removing trisulfide bonds | 11 May, 2032 | Active |
US9316641 | Assay for JC virus antibodies | 09 Jan, 2032 | Active |
US9109015 | Method of isolating biomacromolecules using low pH and divalent cations | 13 Aug, 2031 | Active |
US8809049 | Methods for producing mammalian cells | 22 May, 2031 | Active |
US10308706 | Methods of preventing and removing trisulfide bonds | 05 Feb, 2031 | Active |
US8318416 | Nutrient monitoring and feedback control for increased bioproduct production | 20 Jan, 2031 | Active |
US10444234 | Assay for JC virus antibodies | 11 Jan, 2031 | Active |
US11287423 | Assay for JC virus antibodies | 11 Jan, 2031 | Active |
US9096879 | Method of supplementing culture media to prevent undesirable amino acid substitutions | 07 Jan, 2031 | Active |
US9212379 | Nutrient monitoring and feedback control for increased bioproduct production | 28 Nov, 2030 | Active |
US9005926 | Methods of preventing and removing trisulfide bonds | 01 Oct, 2030 | Active |
US9696307 | Methods for the detection of JC polyoma virus | 05 Feb, 2030 | Active |
US8124350 | Methods and products for evaluating an immune response to a therapeutic protein | 02 Aug, 2027 | Active |
US9493567 | Methods of treating inflammatory and autoimmune diseases with natalizumab | 05 Mar, 2027 | Active |
US10233245 | Methods of treating inflammatory and autoimmune diseases with natalizumab | 28 Feb, 2027 | Active |
US11292845 | Methods of treating inflammatory and autoimmune diseases with natalizumab | 28 Feb, 2027 | Active |
US8871449 | Methods and products for evaluating an immune response to a therapeutic protein | 12 Apr, 2026 | Active |
US10705095 | Methods and products for evaluating an immune response to a therapeutic protein | 04 Apr, 2026 | Active |
US9709575 | Methods and products for evaluating an immune response to a therapeutic protein | 04 Apr, 2026 | Active |
US7157276 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures | 21 Jun, 2024 | Active |
US7759117 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures | 21 Jun, 2024 | Active |
Biogen Inc.'s Family Patents
Biogen Inc. Drug List
Given below is the complete list of Biogen Inc.'s drugs and the patents protecting them.
1. Tysabri
Tysabri is protected by 32 patents, out of which 2 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10844416 | Manganese supplementation for control of glycosylation in mammalian cell culture process |
01 Jun, 2036
(11 years from now)
| Active |
US11268119 | Copper supplementation for control of glycosylation in mammalian cell culture process |
21 Feb, 2036
(11 years from now)
| Active |
US11124760 | Methods for overcoming glutamine deprivation during mammalian cell culture |
27 Aug, 2035
(10 years from now)
| Active |
US10023831 | Gas delivery devices and associated systems and methods |
17 Mar, 2035
(10 years from now)
| Active |
US10676772 | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
19 Aug, 2034
(9 years from now)
| Active |
US9994968 | Electrochemical etching apparatus |
19 Aug, 2034
(9 years from now)
| Active |
US10119976 | Method of assessing risk of PML |
27 May, 2034
(9 years from now)
| Active |
US10677803 | Method of assessing risk of PML |
27 May, 2034
(9 years from now)
| Active |
US11280794 | Method of assessing risk of PML |
27 May, 2034
(9 years from now)
| Active |
US9562252 | Methods of preventing and removing trisulfide bonds |
11 May, 2033
(8 years from now)
| Active |
US10590454 | Methods of preventing and removing trisulfide bonds |
11 May, 2032
(7 years from now)
| Active |
US9790533 | Methods of preventing and removing trisulfide bonds |
11 May, 2032
(7 years from now)
| Active |
US9316641 | Assay for JC virus antibodies |
09 Jan, 2032
(7 years from now)
| Active |
US9109015 | Method of isolating biomacromolecules using low pH and divalent cations |
13 Aug, 2031
(6 years from now)
| Active |
US8809049 | Methods for producing mammalian cells |
22 May, 2031
(6 years from now)
| Active |
US10308706 | Methods of preventing and removing trisulfide bonds |
05 Feb, 2031
(6 years from now)
| Active |
US8318416 | Nutrient monitoring and feedback control for increased bioproduct production |
20 Jan, 2031
(6 years from now)
| Active |
US10444234 | Assay for JC virus antibodies |
11 Jan, 2031
(6 years from now)
| Active |
US11287423 | Assay for JC virus antibodies |
11 Jan, 2031
(6 years from now)
| Active |
US9096879 | Method of supplementing culture media to prevent undesirable amino acid substitutions |
07 Jan, 2031
(6 years from now)
| Active |
US9212379 | Nutrient monitoring and feedback control for increased bioproduct production |
28 Nov, 2030
(6 years from now)
| Active |
US9005926 | Methods of preventing and removing trisulfide bonds |
01 Oct, 2030
(5 years from now)
| Active |
US9696307 | Methods for the detection of JC polyoma virus |
05 Feb, 2030
(5 years from now)
| Active |
US8124350 | Methods and products for evaluating an immune response to a therapeutic protein |
02 Aug, 2027
(2 years from now)
| Active |
US9493567 | Methods of treating inflammatory and autoimmune diseases with natalizumab |
05 Mar, 2027
(2 years from now)
| Active |
US10233245 | Methods of treating inflammatory and autoimmune diseases with natalizumab |
28 Feb, 2027
(2 years from now)
| Active |
US11292845 | Methods of treating inflammatory and autoimmune diseases with natalizumab |
28 Feb, 2027
(2 years from now)
| Active |
US8871449 | Methods and products for evaluating an immune response to a therapeutic protein |
12 Apr, 2026
(1 year, 5 months from now)
| Active |
US10705095 | Methods and products for evaluating an immune response to a therapeutic protein |
04 Apr, 2026
(1 year, 5 months from now)
| Active |
US9709575 | Methods and products for evaluating an immune response to a therapeutic protein |
04 Apr, 2026
(1 year, 5 months from now)
| Active |
US7157276 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
21 Jun, 2024
(3 months ago)
| Expired |
US7759117 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
21 Jun, 2024
(3 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tysabri's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List